ESTUDO PREDIX (ASCO 2019) Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard


ESTUDO PREDIX (ASCO 2019) . ANALISE DE DESCALONAMENTO DE TRATAMENTO NEOADJUVANTE , COMPARANDO DOCETAXEL/TRAST+PERTUZ/ VERSUS TDM1 . 
RESULTADO FINAL SEM DIFERENÇA ESTATISTICA COM ALTAS TAXAS PARA SUBGRUPO DE RECEPTORES HORMONAIS NEGATIVO (HER-2 ENRICHED). NESTE ESTUDO FAZ SE  ANALISE EXPLORATORIA COMPARA-SE IMPORTANCIA DO PETCT , NA PCR .














Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais